PL1737962T3 - Uniwersalny lider GAS1 - Google Patents

Uniwersalny lider GAS1

Info

Publication number
PL1737962T3
PL1737962T3 PL05729650T PL05729650T PL1737962T3 PL 1737962 T3 PL1737962 T3 PL 1737962T3 PL 05729650 T PL05729650 T PL 05729650T PL 05729650 T PL05729650 T PL 05729650T PL 1737962 T3 PL1737962 T3 PL 1737962T3
Authority
PL
Poland
Prior art keywords
heavy chain
chain variable
variable domain
immunoglobulin heavy
domain polypeptide
Prior art date
Application number
PL05729650T
Other languages
English (en)
Inventor
Wildt Rudolph M T De
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of PL1737962T3 publication Critical patent/PL1737962T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/055—Fusion polypeptide containing a localisation/targetting motif containing a signal for localisation to secretory granules (for exocytosis)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Gas Separation By Absorption (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL05729650T 2004-03-24 2005-03-24 Uniwersalny lider GAS1 PL1737962T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55576404P 2004-03-24 2004-03-24
PCT/GB2005/001180 WO2005093074A1 (en) 2004-03-24 2005-03-24 Gas1 universal leader
EP05729650A EP1737962B1 (en) 2004-03-24 2005-03-24 Gas1 universal leader

Publications (1)

Publication Number Publication Date
PL1737962T3 true PL1737962T3 (pl) 2011-02-28

Family

ID=34963448

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05729650T PL1737962T3 (pl) 2004-03-24 2005-03-24 Uniwersalny lider GAS1

Country Status (11)

Country Link
US (1) US7846721B2 (pl)
EP (2) EP2172553A1 (pl)
AT (1) ATE479760T1 (pl)
CY (1) CY1111063T1 (pl)
DE (1) DE602005023291D1 (pl)
DK (1) DK1737962T3 (pl)
ES (1) ES2351509T3 (pl)
PL (1) PL1737962T3 (pl)
PT (1) PT1737962E (pl)
SI (1) SI1737962T1 (pl)
WO (1) WO2005093074A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589800A1 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
EP2364326B1 (en) 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
MX2011008749A (es) 2009-02-19 2011-09-06 Glaxo Group Ltd Variantes de union a anti-albumina de suero mejoradas.
KR101820968B1 (ko) 2009-02-19 2018-01-23 글락소 그룹 리미티드 개선된 항-혈청 알부민 결합 변이체
CN102405236A (zh) 2009-02-19 2012-04-04 葛兰素集团有限公司 改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂
CN102574914A (zh) 2009-07-16 2012-07-11 葛兰素集团有限公司 改进的抗血清清蛋白结合性单可变区
CA2768460A1 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
JP2013500030A (ja) 2009-07-29 2013-01-07 グラクソ グループ リミテッド ＴＧＦ−β受容体ＲＩＩを結合するリガンド
JP2013516967A (ja) 2010-01-14 2013-05-16 グラクソ グループ リミテッド 肝臓標的化ドメイン抗体
WO2011131659A2 (en) 2010-04-21 2011-10-27 Glaxo Group Limited Binding domains
AU2011254559B2 (en) 2010-05-20 2014-09-04 Glaxo Group Limited Improved anti-serum albumin binding variants
US20120077191A1 (en) * 2010-08-11 2012-03-29 Celula, Inc. Genotyping dna
JP2013538566A (ja) 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
MX2013002055A (es) 2010-08-20 2013-07-22 Glaxosmithkline Ip Dev Ltd Variantes anti-enlace de albumina de suero mejodas.
CA2823104A1 (en) 2011-01-06 2012-07-12 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
EP2670778A1 (en) 2011-02-02 2013-12-11 Glaxo Group Limited Novel antigen binding proteins
DK2699601T3 (en) 2011-04-21 2018-04-23 Bristol Myers Squibb Co ANTIBODY POLYPEPTIDES ANTAGONIZING CD40
RU2670491C2 (ru) * 2012-07-05 2018-10-23 Дженентек, Инк. Система экспрессии и секреции
EP3113796A1 (en) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9400600A (pt) * 1994-02-17 1995-10-24 Finep Financiadora De Estudos Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos
US6555310B1 (en) * 1997-04-04 2003-04-29 Biosite Diagnostics, Inc. Polyclonal libraries
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression

Also Published As

Publication number Publication date
DE602005023291D1 (de) 2010-10-14
ES2351509T3 (es) 2011-02-07
PT1737962E (pt) 2010-12-03
WO2005093074A1 (en) 2005-10-06
EP1737962B1 (en) 2010-09-01
CY1111063T1 (el) 2015-06-11
DK1737962T3 (da) 2010-12-13
ATE479760T1 (de) 2010-09-15
EP2172553A1 (en) 2010-04-07
US20070026462A1 (en) 2007-02-01
US7846721B2 (en) 2010-12-07
EP1737962A1 (en) 2007-01-03
SI1737962T1 (sl) 2011-01-31

Similar Documents

Publication Publication Date Title
SI1737962T1 (sl) Univerzalni signalni peptid GAS1
NZ734307A (en) Antibodies specific for claudin 6 (cldn6)
BRPI0519766A2 (pt) proteases Ácidas féngicas
NZ603037A (en) Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
WO2004099376A3 (en) Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity
ATE503009T1 (de) Polypeptide mit lipase-aktivität und diese kodierende polynukleotide
HK1097855A1 (en) Method of detecting probnp with a monoclonal antibody binding to the amino acid 41-46
WO2008005847A3 (en) Method of producing factor viii proteins by recombinant methods
PT1523496E (pt) Produção de misturas de anticorpos de forma recombinante
EP2395092A3 (en) Plants having enhanced yield-related traits and a method for making the same
MX337991B (es) Metodo para detectar cancer.
ATE402267T1 (de) Verfahren zur herstellung von monoklonalen antikörpern
ATE454455T1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
DE60333793D1 (de) Feste oberfläche für biomolekülabgabe und assay mit hoher durchlaufleistung
ATE424458T1 (de) Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung
WO2003004622A3 (en) Human secreted proteins
NZ600540A (en) Ethanol production in non-recombinant hosts
DE502006009060D1 (de) Verfahren zur fermentativen Herstellung von Antikörpern
DK1616878T3 (da) Udskilte og membranspændende polypeptider samt nukleinsyrer kodende for disse
WO2003000865A3 (en) Human secreted proteins
ATE539163T1 (de) Auf der verwendung von mva beruhende impfstoffe
WO2009028531A1 (ja) ドックリンポリペプチドおよびそれを利用した組換え融合タンパク質の精製方法
ATE320484T1 (de) Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
WO2007019064A3 (en) ANTI-TNFα ANTIBODIES AND METHODS OF USE
WO2008008182A3 (en) Method of production of para-hydroxycinnamic acid